Dr. Keith Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial

Prof Keith Stewart at ASH 2014: Phase 3 study of carfilzomib and anti-CD38 therapy in myelomaПодробнее

ASPIRE trial for MM: updates from ASH 2017Подробнее

ASCO 2007 - Dr. Keith Stewart discusses carfilzomib trialПодробнее

06 "Individualizing Cancer Therapy - the Mayo Clinic Experience" Keith StewartПодробнее

Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myelomaПодробнее

Phase III study shows carfilzomib is an effective addition to standard myeloma therapyПодробнее

Myeloma Expert Brian Durie Discusses the ASPIRE TrialПодробнее

Results of the ASPIRE trial for MM: the addition of carfilzomibПодробнее

Dr. Stewart on Carfilzomib Adverse Events in Relapsed Multiple MyelomaПодробнее

Dr Keith Stewart Chairs a Discussion About the Treatment of MyelomaПодробнее

Dr. Richter Discusses the Administration of CarfilzomibПодробнее

Lessons from the ASPIRE trial: three drug regimens as the new SOC for relapsed MMПодробнее

Keith Stewart, M.B., Ch.B.: Internist - Mayo ClinicПодробнее

ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myelomaПодробнее

ASH 2017 top picks: Phase III trials, antibody-drug conjugates and CAR T-cellsПодробнее

Meet the Editor: A. Keith Stewart, MBChBПодробнее

Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myelomaПодробнее

Carfilzomib As Part of Upfront TherapyПодробнее

Adding Carfilzomib to R/R Myeloma RegimensПодробнее